La psoriasis se considera una enfermedad sistémica con múltiples comorbilidades que pueden afectar a otros órganos más allá de la piel. Una de las posibles causas de morbimortalidad precoz de los pacientes con psoriasis es la presencia de factores de riesgo cardiovascular a edades más tempranas y como consecuencia el desarrollo de enfermedades cardiovasculares. No obstante, no está definido si la psoriasis puede ser un factor de riesgo independiente para el desarrollo de enfermedad cardiovascular.
El objetivo principal es determinar si los pacientes con psoriasis son más propensos a desarrollar eventos cardiovasculares en ausencia de los factores de riesgo cardiovascular tradicionales. Para ello se propone un estudio de cohortes retrospectivo, cuya población serán los pacientes atendidos en equipos de atención primaria del ICS en Terres de l’Ebre, con diagnóstico de psoriasis y sin antecedentes de enfermedad cardiovascular que se compararán con pacientes del mismo sexo y franja de edad sin psoriasis y sin antecedentes de enfermedad cardiovascular (proporción 1:4) durante 20 años (2004-2024).
Si se confirmara la hipótesis, este estudio abriría las puertas a nuevos trabajos que analicen los factores relacionados con la psoriasis y así realizar una correcta prevención y cribado de enfermedades cardiovasculares.

On 23 August 2023, PF-06928316 (hereafter ABRYSVO) was approved by the European Commission for active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), a major cause of respiratory illness in older adults. This marketing authorization is valid in all 27 European Union (EU) member states plus Iceland, Liechtenstein, and Norway. On 31 May 2023, the Food and Drug Administration (FDA) approved ABRYSVO for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older.
The EU marketing authorization for ABRYSVO in older adults is based on evidence from the pivotal Phase 3 clinical trial, RENOIR (C3671013, NCT05035212) which evaluated the efficacy, immunogenicity, and safety of a single 120 µg dose of PF-06928316 or prefusion F vaccine in adults 60 years or older.
As immunocompromised, renally and hepatically impaired older adults were not included in clinical trials that supported regulatory approvals, the safety profile of ABRYSVO in these populations is unknown.
This protocol describes a post-authorization safety study (PASS) to assess the safety of ABRYSVO in immunocompromised, or renally or hepatically impaired adults aged 60 and older in select European countries and in the UK, with data sources that can capture vaccine exposure in the target populations, and where outcomes and key covariates can be ascertained. This study is an additional pharmacovigilance activity (Category 3 study) in the approved EU risk management plan (RMP) for ABRYSVO.
Research question and objectives
The research question is: What is the incidence of safety events of interest among immunocompromised, or renally or hepatically impaired adults aged 60 years and older who receive ABRYSVO compared to a relevant comparator group who does not receive ABRYSVO?
The primary study objective is:
To estimate the incidence rates and rate ratios of safety events of interest in immunocompromised, or renally or hepatically impaired adults aged 60 years and older who receive ABRYSVO compared to a relevant comparator group who does not receive ABRYSVO (evaluated as separate populations and if appropriate, as a combined population).
Study design
This is a retrospective, comparative cohort study using data access providers of the Vaccine Monitoring Collaboration for Europe (VAC4EU) that meet fit-for-purpose criteria. If appropriate, based on the outcome of interest, the study will also use a self-controlled risk interval (SCRI) design.
Population
The target population will consist of individuals who are immunocompromised, or renally or hepatically impaired (evaluated as separate populations and if appropriate, as a combined population) who are at least 60 years of age on the date of vaccination (i.e, index date for the vaccinated cohort) or on the matched index date (for the unvaccinated cohort), and who have at least 12 months of medical history in one of the data sources with no record of RSV vaccination in that 12 month period and who have at least one day of post-index follow up. Immunocompromised or renally impaired or hepatically impaired status will be ascertained via coded diagnoses, treatments, procedures, and/or laboratory values, as appropriate, at index date or in the 12-month baseline period prior to the index date.
Variables
The exposure of interest is ABRYSVO vaccination, which will be obtained from pharmacy dispensing records, general practice records, immunization registers, vaccination records, medical records, or other secondary data sources. Outcomes will be identified in participating databases with algorithms based on codes for diagnoses, procedures, and treatments. Standard algorithms for each outcome definition will be applied to participant data sources, based on the results of the ACCESS project, and will be tailored to the data source. Potential covariates may include the following information, as available in each data source: demographics; personal lifestyle characteristics; and clinical characteristics including comorbidities, comedication use, healthcare utilisation descriptors, other vaccinations, and surrogates of frailty. Covariates will be identified on the index date (or during the 12-month baseline period prior to the index date). These variables will be used to further characterize the patient populations of interest and/or to control for confounding.
Data sources
The study will utilise data from the following selected data sources: Clinical Practice Research Datalink (CPRD) Aurum (UK), Valencia Health System Integrated Database (VID) (ES), Sistema d’Informació per el Desenvolupament de la Investigació en Atenció Primària (SIDIAP) [Information System for the Improvement of Research in Primary Care] (ES), EpiChron Research Group on Chronic Diseases at the Aragon Health Sciences Institute (EpiChron) (ES), and Système National des Données de Santé (SNDS) (FR).
Study size
All individuals who meet the eligibility criteria during the study period in the select data sources will be included. The sample size will depend on the number of individuals administered ABRYSVO identified within the data sources during the study period, which will increase over time. The relative increases in rates to be detected will vary across outcomes of interest. For example, analyses using a comparative cohort design will have sufficient power (80%) to detect a 2-fold and 3-fold increased rate of arrhythmia associated with ABRYSVO, with a sample size of 1,178 and 393 individuals per cohort, respectively, assuming a baseline rate of 2,000 arrhythmia events per 100,000 person-years and equal numbers of individuals in the vaccinated and unvaccinated cohorts.
Data analysis
Baseline demographics and clinical characteristics for ABRYSVO vaccinated and unvaccinated individuals will be summarized using descriptive statistics. Descriptive statistics will also be used to summarize ABRYSVO uptake characteristics. Incidence rates per 1,000 patient years (and corresponding 95% CIs) will be calculated for all outcomes of interest in the ARBYSVO vaccinated and unvaccinated cohorts separately.
For the comparative cohort design, outcome specific incidence rates in the ABRYSVO vaccinated cohort will be compared to incidence rates in the unvaccinated cohort. Average treatment effect for the treated (ATT) weighting based on the propensity scores (PS) will be used to ensure baseline comparability between the vaccinated and unvaccinated cohorts. Stabilized inverse probability of censoring weighting (IPCW) will also be used if informative censoring between the cohorts is observed. After weighting, the distribution of baseline characteristics will be evaluated between the vaccinated cohort and the unvaccinated cohort, and variables that are inadequately balanced (standardized difference >10%) between the two cohorts will be included as regression model covariates in a doubly robust approach. Weighted Poisson regression models will be conducted, and incidence rate ratios and corresponding 95% confidence intervals (CIs) will be summarized.
For the SCRI design, the study population will include individuals who have received ABRYSVO, and experienced the specific outcomes of interest during the post-vaccination risk or control interval. Individuals who experienced a prespecified outcome following ABRYSVO vaccination serve as their own control by comparing the incidence of the outcome in the post-vaccination risk interval to the incidence of the outcome in a post-vaccination control interval using a conditional Poisson regression model. From this model, incidence rate ratios and 95% CIs will be reported.
Meta-analysis: Using the main estimates from each data source, appropriate random-effects meta-analytic methods may be used to obtain a combined effect estimate within each population of interest for both the comparative cohort and SCRI design analyses.

Introducción
El lipedema es una enfermedad crónica del tejido adiposo que causa una acumulación simétrica de grasa en las extremidades inferiores, respetando los pies. Afecta principalmente a mujeres y suele confundirse con obesidad o linfedema, lo que favorece su infradiagnóstico. Su diagnóstico es clínico, basado en signos como la distribución simétrica de grasa y la negatividad del signo de Stemmer. El desconocimiento de esta enfermedad entre los profesionales sanitarios dificulta su detección y tratamiento, afectando la calidad de vida de las pacientes.
Hipótesis
Los profesionales sanitarios de atención primaria del área sanitaria de Lleida tienen un conocimiento limitado sobre el diagnóstico del lipedema, lo que podría contribuir al infradiagnóstico y al manejo inadecuado de esta enfermedad en la población afectada.
Objetivo Principal
Averiguar el conocimiento de los profesionales sanitarios de atención primaria del área sanitaria de Lleida sobre el diagnóstico del lipedema.
Metodología
Se realizará un estudio observacional descriptivo de tipo transversal.
Palabras clave:
Lipedema, primary care, medical Subject Headings y health knowledge, attitudes, practice.

Rationale and background
Multiple studies have showed that oral combined hormonal contraception is associated with an increased risk of venous thromboembolism (VTE), especially for high dose combined oral contraception.
Recently, a nationwide study from Denmark reported that NSAIDs use was associated with increased VTE risk in women 15-49 years old, especially among those with concomitant use of high/medium risk hormonal contraception. More data on theassociation of venous thromboembolism with NSAIDs in women of reproductive age has been requested by medicines regulators to see if such associations are seen in other databases , including data on women using hormonal contraception.
Research question and objectives
The study aims to answer the question of: Is there an association with VTE during concomitant use of NSAIDs prescribed to women taking hormonal contraceptive users aged 15-49 years old?
Specific objectives:
1. To characterise the use of oral NSAIDs among women aged 15-49 using hormonal contraceptives.
2. To measure the association of any oral NSAID use and the incidence of VTE among 15-49 years old women on high, medium, and low risk hormonal contraceptives.
3. To measure the association of ibuprofen, diclofenac and naproxen use on the incidence of VTE among 15-49 years old women on high, medium, and low risk hormonal contraceptives.
Methods
Study design
Objective 1 will be a drug utilisation study where new users of oral NSAIDs during the use of hormonal contraceptives will be characterised.
Objectives 2 and 3 will use a self-controlled case series (SCCS) design, nested within a cohort of hormonal contraceptive users.
Data source
This study will be conducted using routinely collected health data (also known as ‘real world data’) from 4 databases in 4 European countries. All databases were previously mapped to the OMOP CDM.
1. Clinical Practice Research Datalink (CPRD GOLD), United Kingdom
2. Danish Data Health Registries (DK-DHR), Denmark
3. Sistema d’Informació per al Desenvolupament de la Investigació en Atenció Primària (SIDIAP), Spain
4. Norwegian Linked Health Registry data (NLHR), Norway
Population
In Objective 1, the study population will be women aged 15-49 who initiate oraloral NSAIDs (ibuprofen, diclofenac and naproxen) during the use of hormonal contraceptives, defined using a 90-day washout window.
In objective 2, study population will include women aged 15-49, included when they start treatment with hormonal contraceptives, and with no history of venous or arterial thromboembolism, cancer (except non-melanoma skin cancer), thrombophilia, hysterectomy, bilateral oophorectomy, sterilisation or infertility treatment. For the SCCS analysis, only women who used NSAIDs as well as having VTE events during the hormonal contraceptive use will be included.
Variables
Hormonal contraceptives will be classified into three groups based on the risk of VTE.
The exposures will be any NSAIDs, and Ibuprofen, diclofenac, and naproxen separately. Ibuprofen, diclofenac, naproxen are most used NSAIDs in Europe. The primary outcome of interest is incident VTE, deep vein thrombosis and pulmonary embolism will be assessed combined and individually.
Other variables include the risk factors of VTE and indications of NSAIDs: recent surgery, trauma/ fracture, cancer, and hospitalisation.
Statistical analysis
Objective 1: Drug utilisation of oral NSAIDs (ibuprofen, diclofenac and naproxen) among women aged 15-49 using hormonal contraceptives.
Among women using hormonal contraceptives who initiate concomitant oral ibuprofen, diclofenac and naproxen, the initial dose and cumulative dose will be assessed at ingredient level for the initial medication. A grace period of 30 days will be used to define the treatment episode. For each drug exposure record in the database, the start date is the dispensing or prescription date, and the end date is defined either by duration or days’ supply, or quantity divided by daily dose. A 90-days washout window will be used to define NSAIDs initiation.
Duration of the treatment episode will be summarised providing the minimum, p25, median, p75, and maximum treatment duration. Number of prescriptions within the treatment episode will be reported. We will also assess the potential indication of NSAIDs during the 7- and 30- days before initiation. Analysis will be conducted for ibuprofen, diclofenac, and naproxen separately.
Objectives 2 and 3: Incidence rate ratio of VTE
For the descriptive analysis, we will conduct large-scale characterisation as well as pre-specified patient-level characteristics of the study population at: i.cohort entry for each contraceptive group (start of hormonal contraceptive); ii.start of NSAIDs exposure (First treatment episode) during hormonal contraceptive use; and iii.time of VTE diagnosis. We will report number and percentage of people who developed conditions that might increase the risk of VTE during each follow-up period.
We will then conduct the self-controlled case series analysis, which compares the incidence rate of events during time exposed to NSAIDs with the rate during all other observed time periods using hormonal contraceptives within individual. We will allocate person-time exposed to hormonal contraceptive into four intervals: Baseline period, defined as on treatment with hormonal contraceptive but not exposed to a NSAIDs; NSAIDs exposure risk period, defined by concomitant use of hormonal contraceptives and NSAIDs; Pre-exposure period: 2-week period before starting NSAIDs (while on hormonal contraceptives); and post-exposure period: 30-day period after stopping using NSAIDs (while still on hormonal contraceptives).
Firstly, we will perform diagnostics to test the assumptions of SCCS analysis, including event-dependent exposures, and event-dependent observation periods.
The SCCS model will be fitted using conditional Poisson regression with an offset of the length of risk
periods. Incidence rate ratios (IRR) and 95% confidence intervals of events will be estimated for the pre-exposure period and the risk periods. Age, and development of health conditions that are risk factors of VTE will be adjusted for as they are time-varying confounders.
All analyses will be conducted for each hormonal contraceptive groups (high, medium, low). In objective 2, we will define the exposure as any NSAIDs. In objective 3, ibuprofen, diclofenac and naproxen will be analysed separately. We will use paracetamol both with or without codeine as a negative control exposure.
Three sensitivity analyses will be performed. In SCCS analysis, if an event increases the probability of death, the assumption of “occurrence of the outcome event does not affect an individual’s time observed” might be violated. Therefore, we will conduct a sensitivity analysis by excluding cases who died within 90 days of VTE outcome. To assess the impact of confounding by indication, that NSAIDs were prescribed to treat conditions which are also risk factors of VTE, we will exclude VTE recorded recorded in the 6 months after cancer, trauma, cancer, or hospitalisation records. We will also conduct a sensitivity analysis by restricting to the first hormonal contraceptives use episode of individuals.

Rationale
Cancer-associated venous thrombosis is relatively common: from 20% to 30% of all primary venous thromboembolic events are cancer-associated. Cancer patients have an increased risk of developing venous thromboembolism (VTE) compared to individuals without underlying malignancies, and it is also recognised as one of the major causes of death in cancer patients. The reported incidence varies across different populations and cancer types and can also be attributed to variations in patient characteristics, clinical management options, and the cancer stage at diagnosis. The incidence of VTE was found to be higher in cases of renal cell, ovarian, pancreatic, stomach, and lung cancers, as well as acute myelogenous leukaemia and non-Hodgkin lymphoma during the four months immediately preceding the cancer diagnosis. When investigating a potential safety signal associated with oncological treatments, the availability of recent and reliable information on the background risk of VTE in cancer patients is crucial.
Research Objectives
This study aims to estimate incidence rates of venous thromboembolic events (deep vein thrombosis (DVT), pulmonary embolisms (PE), venous thromboembolism (VTE, composite of DVT and PE), pelvic venous thrombosis (PVT), splanchnic vein thrombosis (SVT), including hepatic and extra-hepatic vein thrombosis, retinal vein thrombosis (RVT), including retinal central vein thrombosis, and disseminated intravascular coagulation (DIC) in adult patients (aged 18 and above) newly diagnosed with selected cancers ((bone, brain, breast, colorectal, corpus uteri, kidney, leukaemia and lymphoma, liver, lung, melanoma, oesophageal, ovary, pancreas, prostate, stomach) in 2016-2022 and to describe their characteristics at the time of cancer diagnosis.
The specific objectives of the study are:
1. To estimate the incidence rates of thromboembolic events in patients newly diagnosed with each type of selected cancers stratified by country/database, age group, sex, study period (2016-2019 and 2020-2022), and cancer stage one and two years after cancer diagnosis.
1. To characterise cancer patients in terms of demographics, comorbidities and concomitant medication before and at the time of diagnosis, as well as medications and procedures received in the first 90 days after cancer diagnosis.
MODEL DE SOL·LICITUD
2 IMP-126-CT Versió 07
Research Methods
Study design
Population-based cohort study.
Population
The study population will include all individuals aged 18 years and above with a primary diagnosis of one of the selected cancers (bone, brain, breast, colorectal, corpus uteri, kidney, leukaemia and lymphoma, liver, lung, melanoma, oesophageal, ovary, pancreas, prostate, stomach). The study period will be from 01/01/2016 to 31/12/2022, which is at least one year prior to the last date of data availability in all databases to ensure sufficient time to capture potential outcomes of interest. Only patients with the first and one cancer diagnosis (except non-melanoma skin cancer) will be included. Cancer cases and thromboembolic events will be identified based on appropriate computable phenotyping algorithms. Conditions in the OMOP CDM use the Systematised Nomenclature of Medicine (SNOMED) as the standard vocabulary for diagnosis codes. The International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) will also be considered for cancer diagnoses.
Variables
Outcomes will include thromboembolic events, in particular, DVT, PE, VTE (composite of DVT and PE), PVT, SVT, RVT, DIC. The outcomes will be calculated in patients with selected cancer types and stratified by the American Joint Committee on Cancer and the International Union Against AJCC/UICC stage categories, age (18-34, 35-44, 45-54, 55-64, 65-74, 75-84 and 85 and above), sex and study year.
Data sources
1. Clinical Practice Research Datalink GOLD (CPRD GOLD), United Kingdom
2. Danish Data Health Registries (DK-DHR), Denmark
3. Estonian Biobank (EBB), Estonia
4. Finnish Care Register for Health Care (FinOMOP-HILMO) Finland
5. Hospital District of Helsinki and Uusimaa (FinOMOP-HUS), Finland
6. IQVIA Disease Analyzer Germany (IQVIA DA Germany), Germany
7. IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium), Belgium
8. Integrated Primary Care Information (IPCI), Netherlands
9. The Information System for Research in Primary Care (SIDIAP), Spain.
10. UK Biobank (UKBB), United Kingdom
Sample size
No sample size will be calculated as this is a descriptive study.
Data analyses
Analyses will be conducted separately for each database and carried out in a federated manner, allowing analyses to be run locally without sharing patient-level data.
The incidence of thromboembolic events (Objective 1) will be estimated over one and two years after the selected cancer diagnosis. Each cancer type and outcome will be assessed separately. Large-scale patient-level characterisation (Objective 2) will be conducted at the index date. Age and sex will be described at the time of diagnosis. The medical history and medication will be assessed at the index date.
For all analyses, absolute and relative frequencies will be reported. A minimum cell count of 5 will be used when reporting results, with any smaller counts reported as “<5” and zero counts as “0”. Overall analyses will be done separately for each database. Stratification by age category, sex, study year, cancer stage will be conducted when possible (minimum cell count reached and data available).

La violencia de género es un fenómeno que ocupa y preocupa, siendo hace décadas un eje prioritario en las agendas políticas. Atenta contra los derechos humanos y contra la salud pública, razón por la cual se inscribe dentro de los objetos de intervención propios del trabajo social (Almendros et al., 2015; Gálligo, 2005; IFSW, 2014). De hecho, es considerado un objeto de intervención casi tan antiguo como la misma profesión (Santana, 2010). Sin embargo, cabe destacar la exigüidad de estudios existentes en materia y la aparente escisión entre la teoría y la práctica (Romero, 2019).
La presente investigación tiene por finalidad aproximarse a la práctica de las trabajadoras sociales sanitarias, en materia de violencia de género, en los Centros de Atención Primaria (CAP) de la ciudad de Barcelona. Busca comprender los aspectos subjetivos que motivan e infieren en su quehacer desde la subjetividad y la perspectiva significativo-experiencial. Para ello se ha optado por un diseño metodológico cualitativo afín a la perspectiva teórico-metodológica empleada en el estudio, la fenomenología. Tomando como marco referencial principal la fenomenología social schütziana.
A modo de resultados, se espera recoger de manera holista la experiencia subjetiva individual de las profesionales respecto al objeto de la violencia de género,profundizando sobre cómo se comprende, se significa y se vivencia. Pretende dilucidar los entresijos y elementos subjetivos que propician o toman cierta relevancia en el acontecer de sus intervenciones profesionales.

INTRODUCCIÓN:
El Virus de la Inmunodeficiencia Humana (VIH) sigue siendo uno de los principales problemas de salud pública a nivel mundial. En España, en el 2022, se notificaron 2956 nuevos diagnósticos, de los cuales el 48,6% fueron tardíos y el 27,6% concurrieron con enfermedad avanzada. La mayoría de ellos habían acudido a los Centros de Atención Primaria (CAP) previo al diagnóstico, con consultas relacionadas con el VIH o tenían en su historia clínica un factor de riesgo o una condición indicadora (CI) de posible infección por VIH. Una estrategia para alcanzar los objetivos 95-95-95 de la OMS para el 2030 es dirigir las pruebas de VIH entre los pacientes con condiciones indicadoras.
OBJETIVO:
Evaluar el impacto de una intervención formativa dirigida a profesionales de Atención Primaria (AP) de la zona de influencia del Hospital de Viladecans en: 1) el incremento del número de solicitudes de serología de VIH entre los pacientes diagnosticados de una condición indicadora (CI) de VIH atendidos en AP, y 2) en la mejora del conocimiento de los profesionales.
METODOLOGIA:
Estudio cuasi-experimental, con tres ramas, en 8 Centros de AP. Se realizará una intervención formativa en abril y mayo de 2026 en tres equipos de AP docentes (Grupo intervención A), así como en dos equipos no docentes (Grupo intervención B). Se utilizarán como grupo control otros tres equipos de la zona de referencia del Hospital de Viladecans. Se evaluará el impacto mediante el incremento de solicitudes de serología de VIH ante una nueva CI, antes y después de la intervención, y la mejora del conocimiento mediante el cuestionario OptTEST.
RESULTADOS ESPERADOS :
Se espera que tras realizar sesiones formativas sobre el VIH, aumente el número de serologías y por consiguiente el número de diagnósticos de VIH.
ÉTICA Y PROTECCIÓN DE DATOS :
Se enviará el protocolo al Comité de Ética de Investigación (CEI) para su aprobación.

Background:
Social Prescribing (SP) means referring patients in primary care to social activities within their community that could improve their health and well-being, often addressing isolation and loneliness. SP programmes are being widely promoted in the UK. Although they are now being increasingly adopted all over Europe, their formats differ and depend on the healthcare system and facilities in the country/region.
Our previous studies on SP confirmed that there is a need to clarify more to health professionals what social prescribing is dealing with. Therefore, this proposed study aims to map across Europe established SP programmes, how they are organised and implemented within healthcare systems.
Research questions:
What key ingredients contribute to successful social prescribing programs within European primary care settings, as identified by European experts?
Method:
In this qualitative, multi-country study the steering group will develop an open-ended questionnaire. The first draft of the questionnaire will be based on the research objectives, the results of our preliminary study on the topic and an extensive literature review. Subsequently, a panel of Primary Health Care experts and methodology experts will use a Delphi process to evaluate the validity of the items, the length of the questionnaire, formulate suggested changes, and identify missing items. The research team will then discuss
all feedback until consensus will be reached, and a final version of the questionnaire will be developed.
Describe your plans to disseminate information/results both during and at the conclusion of your project
Scientific manuscripts will be submitted to peer reviewed medical journals. Preliminary and definitive outcomes will be presented at EGPRN and WONCA Europe meetings.

– ANTECEDENTS: La diabetis tipus 2 (DM2) és una condició cada vegada més prevalent que afecta especialment la població d’edat avançada. El control insuficient de la malaltia, redueix la qualitat i esperança de vida de les persones afectades, principalment arran de l’aparició de complicacions vasculars i cròniques. Entre els factors que influeixen en aquest mal control, trobem la presència de determinants socials de la salut adversos i la coexistència amb la fragilitat, que més sovint es presenta durant l’envelliment.
– HIPÒTESI: Les persones amb DM2 i fragilitat presenten una càrrega més elevada de comorbiditats i pitjors resultats en salut (més complicacions de la diabetis, hospitalitzacions, mortalitat) en comparació amb les persones amb DM2 sense diabetis. També presenten major risc de sobretractament farmacològic a causa de l’infradiagnòstic de la fragilitat i falta d’adaptació dels objectius terapèutics.
– OBJECTIUS: L’objectiu que es preté és conèixer la prevalença de la fragilitat en pacients amb DM2, identificar factors de risc i determinants socials associats, així com la presència d’altres comorbiditats, complicacions i tractaments de la diabetis.
– METODOLOGIA: Estudi observacional de cohorts retrospectives i multicèntric.
– DETERMINACIONS: No procedeix.
– ANÀLISI ESTADÍSTICA: S’analitzarà una cohort de pacients amb DM2 i una cohort de control sense DM2, aparellades per edat i sexe. La DM2 es definirà per la presència d’un codi diagnòstic CIE-10, l’ús de fàrmacs
antidiabètics, o una HbA1c = 6,5%. S’inclouran pacients diagnosticats entre 2010 i 2023 que compleixin els criteris d’inclusió i exclusió establerts. La fragilitat es determinarà amb l’índex validat eFRAGICAP, que classifica els pacients segons el grau de fragilitat a partir de les dades clíniques disponibles.
– RESULTATS ESPERATS: S’espera evidenciar una prevalença elevada de fragilitat en pacients amb DM2, amb una associació significativa entre els SDOH desfavorables i pitjors resultats de salut. També es preveu identificar diferències significatives en el grau de control metabòlic, les complicacions de la malaltia, hospitalitzacions i mortalitat entre els grups estudiats.
– APLICABILITAT I RELLEVÀNCIA: Els resultats d’aquest estudi contribuiran a millorar la detecció precoç de la fragilitat i l’estratificació del risc de presentar-la; optimitzar el maneig clínic personalitzat dels pacients fràgils amb DM2; i ajustar protocols clínics, informar polítiques sanitàries dirigides a minimitzar desigualtats socials en salut.

Antecedentes: los anticoagulantes orales de acción directa (ACOD) han demostrado tener un perfil de seguridad mayor que los fármacos anti-vitamina K. Se ha demostrado la eficacia de los ACOD en la prevención de complicaciones tromboembólicas con una mayor seguridad en cuanto a complicaciones hemorrágicas. En Cataluña, la prescripción de ACOD oscila en un rango entre 35-45%. Creemos fundamental apostar por el refuerzo en la formación clínica de los profesionales sanitarios de Atención Primaria y la alianza con los pacientes para promover la concienciación y el conocimiento en la instauración de los ACODS como tratamiento farmacológico anticoagulante, siempre que se adapte a sus necesidades, garantizando una correcta praxis y abordaje terapéutico.
Hipótesis: el nivel de conocimientos de los profesionales sanitarios de los centros de Atención Primaria de Cataluña Central sobre el uso y la adherencia al tratamiento de ACODS es insuficiente.
Objetivos: investigar el nivel de conocimientos que tienen los profesionales sanitarios de Cataluña Central respecto al manejo de los ACOD, además de comparar y evaluar el nivel de conocimientos según características sociodemográficas y perfil profesional.
Metodología: se diseña un estudio descriptivo y transversal, a través de la descripción de conocimientos de los profesionales de la salud sobre ACOD, mediante un cuestionario on-line. La finalidad es analizar los datos de las variables recopiladas en un periodo de tiempo concreto sobre profesionales de la salud que cumplan los criterios de inclusión del estudio y trabajen en los centros de atención primaria del área de Cataluña Central.
Aplicabilidad y Relevancia: demostrar los conocimientos que tienen los profesionales sanitarios de los centros de salud del área de Cataluña Central sobre ACODS para conocer las necesidades formativas que se necesitan reforzar sobre este tema y así proporcionar una mejor atención a los pacientes, basando la práctica clínica en evidencia actualizada.